Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases

McCubrey, James A.; Lertpiriyapong, Kvin; Steelman, Linda S.; Abrams, Steve L.; Cocco, Lucio; Ratti, Stefano; Martelli, Alberto M.; Candido, Saverio; Libra, Massimo; Montalto, Giuseppe; Cervello, Melchiorre; Gizak, Agnieszka; Rakus, Dariusz

doi:10.1016/j.jbior.2017.05.005

Cited by 38 publications

(16 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Berberine is used for the treatment and prevention of various diseases world-wide now (McCubrey et al, 2017a(McCubrey et al, , 2017b(McCubrey et al, , 2017c(McCubrey et al, , 2017dMcCubrey and Cocco, 2017). Berberine are naturally present in many fruits and plants including: Berberis aetnensis C.…”

Section: Discussionmentioning

confidence: 99%

“…Berberine is a natural product obtained from various berries and fruits (McCubrey et al, 2017a(McCubrey et al, , 2017b. It can have multiple effects on cells, one is on the induction of NF-kappa B, another may be the induction of AMPK.…”

Section: Effects Of Combining a Suboptimal Dose Of Metformin With Thementioning

confidence: 99%

“…KRAS is often normally activated by various growth factor receptors and is part of the RAS/RAF/ERK, PI3K/PTEN/AKT/mTORC1/ GSK-3 and other interacting signaling pathways. The roles of these and other signaling pathways in various disorders, cancer and development have been recently reviewed (McCubrey et al, 2014a(McCubrey et al, , 2014bChappell et al, 2016;Ghim et al, 2016;Giudici et al, 2016;Kang et al, 2016;McCubrey et al, 2016;Yang et al, 2016;Cervello et al, 2017;Jhanwar-Uniyal et al, 2017;McCubrey et al, 2017aMcCubrey et al, , 2017bMcCubrey et al, , 2017cMcCubrey et al, , 2017dPappas et al, 2017;Ruvolo, 2017;Ryuno et al, 2017). As KRAS has been frequently observed to be mutated in pancreatic cancer, attempts have been developed to generate effective RAS inhibitors as well as additional signaling molecules in this pathway.…”

Section: Introductionmentioning

confidence: 99%

“…As KRAS has been frequently observed to be mutated in pancreatic cancer, attempts have been developed to generate effective RAS inhibitors as well as additional signaling molecules in this pathway. Attempts to inhibit the RAS/PI3K/PTEN/Akt/mTORC1/GSK-3 and other signaling pathways have been a central focus in many basic science laboratories and pharmaceutical companies for over three decades due to the involvement oncogenes in this pathway in human cancers (Yang et al, 2013;Fitzgerald et al, 2015;McCubrey et al, 2015;Anderson et al, 2016;Banfic et al, 2016;Cocco et al, 2016;Erneux et al, 2016;Falasca and Ferro, 2016;Fields et al, 2016;Geck and Toker, 2016;Maczis et al, 2016;Perdios et al, 2016;Pyne et al, 2016;Scarlata et al, 2016;Scoumanne et al, 2016;Tanaka et al, 2016;Ando et al, 2017;Carman and Han, 2017;Fujisawa, 2017;Geffken and Spiegel, 2017;Guo et al, 2017;Jang et al, 2017;Leonard and Johnson, 2017;Liu et al, 2017;Matsuzawa, 2017;McCubrey et al, 2017aMcCubrey et al, , 2017bMcCubrey et al, , 2017cMcCubrey et al, , 2017dObsil and Obsilova, 2017;Okazaki, 2017;Pyne et al, 2017;Ramos et al, 2017;Ratti et al, 2017;Rebello et al, 2017;Roth and Frohman, 2017;Rusnak and Fu, 2017;…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Metformin influences drug sensitivity in pancreatic cancer cells

Candido

Abrams

Steelman

et al. 2018

Advances in Biological Regulation

Self Cite

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five-year survival of only 5-10% after diagnosis and treatment. Pancreatic cancer has been associated with type II diabetes as the frequency of recently diagnosed diabetics that develop pancreatic cancer within a 10-year period of initial diagnosis of diabetes in increased in comparison to non-diabetic patients. Metformin is a very frequently prescribed drug used to treat type II diabetes. Metformin acts in part by stimulating AMP-kinase (AMPK) and results in the suppression of mTORC1 activity and the induction of autophagy. In the following studies, we have examined the effects of metformin in the presence of various chemotherapeutic drugs, signal transduction inhibitors and natural products on the growth of three different PDAC lines. Metformin, by itself, was not effective at suppressing growth of the pancreatic cancer cell lines at concentration less than 1000 nM, however, in certain PDAC lines, a suboptimal dose of metformin (250 nM) potentiated the effects of various chemotherapeutic drugs used to treat pancreatic cancer (e.g., gemcitabine, cisplatin, 5-fluorouracil) and other cancer types (e.g., doxorubicin, docetaxel). Furthermore, metformin could increase anti-proliferative effects of mTORC1 and PI3K/mTOR inhibitors as well as natural products such as berberine and the anti-malarial drug chloroquine in certain PDAC lines. Thus, metformin can enhance the effects of certain drugs and signal transduction inhibitors which are used to treat pancreatic and various other cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Effects Of Combining a Suboptimal Dose Of Metformin With Thementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Metformin influences drug sensitivity in pancreatic cancer cells

Candido

Abrams

Steelman

et al. 2018

Advances in Biological Regulation

Self Cite

View full text Add to dashboard Cite

show abstract

“…These studies strongly suggest that active GSK3(β) is a potent driver of inflammation in vivo, whereas its inactivation has a mitigating influence. In consequence, the treatment with GSK3β-Ser9 phosphorylation-inducing substances, including a variety of natural products [21], generally dampens signs of (exaggerated) inflammation and tissue damage.…”

Section: Animal Models Of Inflammatory Diseasesmentioning

confidence: 99%

GSK3: A Kinase Balancing Promotion and Resolution of Inflammation

Hoffmeister

Diekmann

Brand

et al. 2020

Cells

View full text Add to dashboard Cite

GSK3 has been implicated for years in the regulation of inflammation and addressed in a plethora of scientific reports using a variety of experimental (disease) models and approaches. However, the specific role of GSK3 in the inflammatory process is still not fully understood and controversially discussed. Following a detailed overview of structure, function, and various regulatory levels, this review focusses on the immunoregulatory functions of GSK3, including the current knowledge obtained from animal models. Its impact on pro-inflammatory cytokine/chemokine profiles, bacterial/viral infections, and the modulation of associated pro-inflammatory transcriptional and signaling pathways is discussed. Moreover, GSK3 contributes to the resolution of inflammation on multiple levels, e.g., via the regulation of pro-resolving mediators, the clearance of apoptotic immune cells, and tissue repair processes. The influence of GSK3 on the development of different forms of stimulation tolerance is also addressed. Collectively, the role of GSK3 as a kinase balancing the initiation/perpetuation and the amelioration/resolution of inflammation is highlighted.

show abstract

Standardized Turmeric and Curcumin

Chand¹

2019

Nutraceuticals in Veterinary Medicine

View full text Add to dashboard Cite

Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases

Cited by 38 publications

References 108 publications

Metformin influences drug sensitivity in pancreatic cancer cells

Metformin influences drug sensitivity in pancreatic cancer cells

GSK3: A Kinase Balancing Promotion and Resolution of Inflammation

Standardized Turmeric and Curcumin

Contact Info

Product

Resources

About